LD-2 disclosure · 4th Quarter - Report
ADAPTIVE BIOTECHNOLOGIES
Client
- Description
- Biotechnology company focusing on immune-driven medicine
- Location
- Washington · United States of America
Registrant
- Description
- Law firm
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
3 issuesHealth Issues
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (H.R. 4128/S. 2209), the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S. 4348), and the Consolidated Appropriations Act, 2023 (P.L. No: 117-328).
LobbyistsKRISTINE BLACKWOOD · PARI MODY · EUGENIA PIERSON · CASEY BROUHARD · BOBBY MCMILLIN · mr PETER ERIC DUYSHART
TargetedSENATE · HOUSE OF REPRESENTATIVES · White House Office · Health & Human Services, Dept of (HHS) · Centers For Medicare and Medicaid Services (CMS)
Budget/Appropriations
Federal funding support for cellular immunity research and utilization; including Fiscal Year 2022 (H.R. 4502) and Fiscal Year 2023 Labor, Health and Human Services, and Education, and Related Agencies appropriations issues (S. 4659; H.R. 8295), Fiscal Year 2023 Department of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations issues (S. 4661; H.R. 8239; H.R. 8294), and the Consolidated Appropriations Act, 2023 (P.L. 117-328).
LobbyistsKRISTINE BLACKWOOD · PARI MODY · EUGENIA PIERSON · CASEY BROUHARD · BOBBY MCMILLIN · mr PETER ERIC DUYSHART
TargetedSENATE · HOUSE OF REPRESENTATIVES
Medicare/Medicaid
